Literature DB >> 15525515

Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance.

Bin He1, Robert T Gampe, Adam J Kole, Andrew T Hnat, Thomas B Stanley, Gang An, Eugene L Stewart, Rebecca I Kalman, John T Minges, Elizabeth M Wilson.   

Abstract

The androgen receptor (AR) is required for male sex development and contributes to prostate cancer cell survival. In contrast to other nuclear receptors that bind the LXXLL motifs of coactivators, the AR ligand binding domain is preferentially engaged in an interdomain interaction with the AR FXXLF motif. Reported here are crystal structures of the ligand-activated AR ligand binding domain with and without bound FXXLF and LXXLL peptides. Key residues that establish motif binding specificity are identified through comparative structure-function and mutagenesis studies. A mechanism in prostate cancer is suggested by a functional AR mutation at a specificity-determining residue that recovers coactivator LXXLL motif binding. An activation function transition hypothesis is proposed in which an evolutionary decline in LXXLL motif binding parallels expansion and functional dominance of the NH(2)-terminal transactivation domain in the steroid receptor subfamily.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15525515     DOI: 10.1016/j.molcel.2004.09.036

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  109 in total

1.  Androgen receptor exon 1 mutation causes androgen insensitivity by creating phosphorylation site and inhibiting melanoma antigen-A11 activation of NH2- and carboxyl-terminal interaction-dependent transactivation.

Authors:  William H Lagarde; Amanda J Blackwelder; John T Minges; Andrew T Hnat; Frank S French; Elizabeth M Wilson
Journal:  J Biol Chem       Date:  2012-02-13       Impact factor: 5.157

Review 2.  Allosteric modulators of steroid hormone receptors: structural dynamics and gene regulation.

Authors:  Raj Kumar; Iain J McEwan
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

Review 3.  Small molecule inhibitors as probes for estrogen and androgen receptor action.

Authors:  David J Shapiro; Chengjian Mao; Milu T Cherian
Journal:  J Biol Chem       Date:  2010-12-13       Impact factor: 5.157

4.  Native functions of the androgen receptor are essential to pathogenesis in a Drosophila model of spinobulbar muscular atrophy.

Authors:  Natalia B Nedelsky; Maria Pennuto; Rebecca B Smith; Isabella Palazzolo; Jennifer Moore; Zhiping Nie; Geoffrey Neale; J Paul Taylor
Journal:  Neuron       Date:  2010-09-23       Impact factor: 17.173

Review 5.  Structural and functional insights into nuclear receptor signaling.

Authors:  Lihua Jin; Yong Li
Journal:  Adv Drug Deliv Rev       Date:  2010-08-17       Impact factor: 15.470

6.  Ultrafast protein structure-based virtual screening with Panther.

Authors:  Sanna P Niinivehmas; Kari Salokas; Sakari Lätti; Hannu Raunio; Olli T Pentikäinen
Journal:  J Comput Aided Mol Des       Date:  2015-09-25       Impact factor: 3.686

7.  Aberrant E2F activation by polyglutamine expansion of androgen receptor in SBMA neurotoxicity.

Authors:  Eriko Suzuki; Yue Zhao; Saya Ito; Shun Sawatsubashi; Takuya Murata; Takashi Furutani; Yuko Shirode; Kaoru Yamagata; Masahiko Tanabe; Shuhei Kimura; Takashi Ueda; Sally Fujiyama; Jinseon Lim; Hiroyuki Matsukawa; Alexander P Kouzmenko; Toshiro Aigaki; Tetsuya Tabata; Ken-ichi Takeyama; Shigeaki Kato
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-23       Impact factor: 11.205

8.  Coregulator control of androgen receptor action by a novel nuclear receptor-binding motif.

Authors:  Katja Jehle; Laura Cato; Antje Neeb; Claudia Muhle-Goll; Nicole Jung; Emmanuel W Smith; Victor Buzon; Laia R Carbó; Eva Estébanez-Perpiñá; Katja Schmitz; Ljiljana Fruk; Burkhard Luy; Yu Chen; Marc B Cox; Stefan Bräse; Myles Brown; Andrew C B Cato
Journal:  J Biol Chem       Date:  2014-02-12       Impact factor: 5.157

9.  Systematic structure-function analysis of androgen receptor Leu701 mutants explains the properties of the prostate cancer mutant L701H.

Authors:  Dennis J van de Wijngaart; Michel Molier; Scott J Lusher; Remko Hersmus; Guido Jenster; Jan Trapman; Hendrikus J Dubbink
Journal:  J Biol Chem       Date:  2009-12-10       Impact factor: 5.157

10.  Rational design of novel antiandrogens for neutralizing androgen receptor function in hormone refractory prostate cancer.

Authors:  Pratap Singh; Gurulingappa Hallur; Ravi K Anchoori; Oladapo Bakare; Yukio Kageyama; Saeed R Khan; John T Isaacs
Journal:  Prostate       Date:  2008-10-01       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.